Teacher Retirement System of Texas grew its position in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 47.9% during the fourth quarter, according to its most recent filing with the SEC. The firm owned 1,301,053 shares of the biopharmaceutical company’s stock after acquiring an additional 421,437 shares during the period. Teacher Retirement System of Texas owned about 0.10% of Gilead Sciences worth $93,207,000 at the end of the most recent quarter.
Several other hedge funds have also recently bought and sold shares of the business. BlackRock Inc. grew its holdings in shares of Gilead Sciences by 1.9% during the 2nd quarter. BlackRock Inc. now owns 104,906,494 shares of the biopharmaceutical company’s stock worth $7,425,281,000 after acquiring an additional 1,937,031 shares during the period. Vanguard Group Inc. grew its stake in shares of Gilead Sciences by 2.4% in the 2nd quarter. Vanguard Group Inc. now owns 92,841,960 shares of the biopharmaceutical company’s stock worth $6,571,355,000 after buying an additional 2,148,697 shares during the last quarter. FMR LLC grew its stake in shares of Gilead Sciences by 1.1% in the 2nd quarter. FMR LLC now owns 23,037,303 shares of the biopharmaceutical company’s stock worth $1,630,581,000 after buying an additional 258,005 shares during the last quarter. Parnassus Investments CA grew its stake in shares of Gilead Sciences by 2.5% in the 4th quarter. Parnassus Investments CA now owns 19,159,748 shares of the biopharmaceutical company’s stock worth $1,372,604,000 after buying an additional 464,609 shares during the last quarter. Finally, Northern Trust Corp grew its stake in shares of Gilead Sciences by 0.7% in the 2nd quarter. Northern Trust Corp now owns 16,430,476 shares of the biopharmaceutical company’s stock worth $1,162,949,000 after buying an additional 116,780 shares during the last quarter. Hedge funds and other institutional investors own 77.83% of the company’s stock.
Several analysts recently weighed in on GILD shares. Maxim Group set a $94.00 price target on Gilead Sciences and gave the stock a “buy” rating in a research note on Monday, December 11th. Credit Suisse Group restated a “buy” rating and issued a $82.00 price target on shares of Gilead Sciences in a research note on Thursday, December 7th. Vetr downgraded Gilead Sciences from a “strong-buy” rating to a “buy” rating and set a $90.00 price target on the stock. in a research note on Wednesday, January 17th. Jefferies Group upgraded Gilead Sciences from a “hold” rating to a “buy” rating and upped their price target for the stock from $81.19 to $93.00 in a research note on Friday, January 26th. Finally, Citigroup upgraded Gilead Sciences from a “neutral” rating to a “buy” rating and cut their price target for the stock from $88.80 to $76.00 in a research note on Tuesday, January 30th. One analyst has rated the stock with a sell rating, ten have assigned a hold rating, seventeen have issued a buy rating and two have given a strong buy rating to the stock. The company presently has an average rating of “Buy” and an average price target of $88.61.
GILD stock opened at $76.92 on Wednesday. The stock has a market capitalization of $101,103.33, a P/E ratio of 9.04, a P/E/G ratio of -1.77 and a beta of 1.24. Gilead Sciences, Inc. has a 12-month low of $63.76 and a 12-month high of $89.54. The company has a debt-to-equity ratio of 1.53, a current ratio of 2.74 and a quick ratio of 2.67.
Gilead Sciences (NASDAQ:GILD) last released its quarterly earnings results on Tuesday, February 6th. The biopharmaceutical company reported $1.78 earnings per share for the quarter, beating the consensus estimate of $1.67 by $0.11. The firm had revenue of $5.95 billion for the quarter, compared to analysts’ expectations of $5.71 billion. Gilead Sciences had a return on equity of 50.29% and a net margin of 17.73%. The company’s revenue was down 18.7% compared to the same quarter last year. During the same period in the prior year, the firm earned $2.70 EPS. equities analysts anticipate that Gilead Sciences, Inc. will post 6.21 earnings per share for the current fiscal year.
The company also recently declared a quarterly dividend, which will be paid on Thursday, March 29th. Stockholders of record on Friday, March 16th will be issued a dividend of $0.57 per share. This represents a $2.28 annualized dividend and a dividend yield of 2.96%. This is a boost from Gilead Sciences’s previous quarterly dividend of $0.52. The ex-dividend date is Thursday, March 15th. Gilead Sciences’s dividend payout ratio is presently 65.52%.
In other news, Director John Francis Cogan sold 5,833 shares of the stock in a transaction on Friday, March 16th. The stock was sold at an average price of $80.09, for a total transaction of $467,164.97. Following the transaction, the director now directly owns 58,452 shares of the company’s stock, valued at approximately $4,681,420.68. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Also, CFO Robin L. Washington sold 5,000 shares of the stock in a transaction on Wednesday, February 28th. The shares were sold at an average price of $80.31, for a total value of $401,550.00. Following the transaction, the chief financial officer now directly owns 23,749 shares in the company, valued at $1,907,282.19. The disclosure for this sale can be found here. Insiders have sold a total of 436,101 shares of company stock worth $34,541,560 over the last three months. Insiders own 1.30% of the company’s stock.
TRADEMARK VIOLATION NOTICE: This story was originally posted by The Ledger Gazette and is the property of of The Ledger Gazette. If you are reading this story on another publication, it was copied illegally and republished in violation of U.S. and international copyright laws. The legal version of this story can be viewed at https://ledgergazette.com/2018/03/21/gilead-sciences-inc-gild-shares-bought-by-teacher-retirement-system-of-texas.html.
Gilead Sciences Profile
Gilead Sciences, Inc is a research-based biopharmaceutical company that discovers, develops and commercializes medicines in areas of unmet medical need. The Company’s portfolio of products and pipeline of investigational drugs includes treatments for Human Immunodeficiency Virus/Acquired Immune Deficiency Syndrome (HIV/AIDS), liver diseases, cancer, inflammatory and respiratory diseases and cardiovascular conditions.
Receive News & Ratings for Gilead Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences and related companies with MarketBeat.com's FREE daily email newsletter.